341 related articles for article (PubMed ID: 18280334)
1. Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
Cen P; Duvic M; Cohen PR; Kurzrock R
J Am Acad Dermatol; 2008 Mar; 58(3):382-6. PubMed ID: 18280334
[TBL] [Abstract][Full Text] [Related]
2. Mycosis fungoides associated with B-cell malignancies.
Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
[TBL] [Abstract][Full Text] [Related]
3. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
4. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
5. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
6. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
Dolan ME; McRae BL; Ferries-Rowe E; Belanich M; van Seventer GA; Guitart J; Pezen D; Kuzel TM; Yarosh DB
Clin Cancer Res; 1999 Aug; 5(8):2059-64. PubMed ID: 10473086
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and treatment of skin T-cell lymphoma undergoing transformation in lymphosarcoma].
Vinogradova IuE; Iliushkina EA; Kaplanskaia IB; Lutsenko IN; Zybunova EE; Kremenetskaia AM; Vorob'ev AI
Ter Arkh; 2009; 81(7):57-61. PubMed ID: 19708575
[TBL] [Abstract][Full Text] [Related]
8. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides--a review of the management of 28 patients and of the recent literature.
Lenane P; Powell FC; O'Keane C; Dervan P; O'Sullivan D; Bourke E; O'Loughlin S
Int J Dermatol; 2007 Jan; 46(1):19-26. PubMed ID: 17214715
[TBL] [Abstract][Full Text] [Related]
10. [Mycosis fungoides. Clinical study and immunologic response to chemotherapy in 2 cases].
Sandoval CA; Garbayo JM; Temiño MA; Valdivia L; Subira ML; Quintanilla E
Med Cutan Ibero Lat Am; 1983; 11(5):357-64. PubMed ID: 6366393
[TBL] [Abstract][Full Text] [Related]
11. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
[TBL] [Abstract][Full Text] [Related]
12. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
13. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH
J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
15. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides.
Demierre MF; Vachon L; Ho V; Sutton L; Cato A; Leyland-Jones B
Arch Dermatol; 2003 May; 139(5):624-8. PubMed ID: 12756099
[TBL] [Abstract][Full Text] [Related]
16. Soluble IL2 receptor serum levels and epidermal cytokines in mycosis fungoides and related disorders.
Zachariae C; Larsen CS; Kaltoft K; Deleuran B; Larsen CG; Thestrup-Pedersen K
Acta Derm Venereol; 1991; 71(6):465-70. PubMed ID: 1685826
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor-gamma gene analysis in evolving to advancing cutaneous T-cell lymphoma.
Foo CC; Tang MB; Chong TK; Sun YJ; Tan SH
Australas J Dermatol; 2007 Aug; 48(3):156-60. PubMed ID: 17680965
[TBL] [Abstract][Full Text] [Related]
18. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study.
Apisarnthanarax N; Talpur R; Ward S; Ni X; Kim HW; Duvic M
J Am Acad Dermatol; 2004 Apr; 50(4):600-7. PubMed ID: 15034511
[TBL] [Abstract][Full Text] [Related]
19. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
Kessler JF; Jones SE; Levine N; Lynch PJ; Booth AR; Meyskens FL
Arch Dermatol; 1987 Feb; 123(2):201-4. PubMed ID: 2949706
[TBL] [Abstract][Full Text] [Related]
20. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.
Herro E; Dicaudo DJ; Davis MD; Weaver AL; Swanson DL
J Am Acad Dermatol; 2009 Aug; 61(2):271-5. PubMed ID: 19481294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
